Literature DB >> 9233713

Portal venous transfusion up-regulates Kupffer cell cyclooxygenase activity: a mechanism of immunosuppression in organ transplantation.

R V Perez1, C Swanson, M Morgan, K Erickson, N E Hubbard, J B German.   

Abstract

Portal venous transfusions (PVTs) of blood have been shown to induce significant immunosuppression in animal models of organ transplantation. A proposed mechanism of PVT-induced immunosuppression is via alteration of Kupffer cell arachidonic acid metabolism with increased secretion of the suppressive metabolite prostaglandin E2 (PGE2). This study assessed the hypothesis that PVT increases Kupffer cell PGE2 production via up-regulation of Kupffer cell phospholipase A2 (PLA2) as well as constitutive (COX1) and inducible (COX2) cyclooxygenase. Kupffer cells from Lewis rats were harvested 1 hr after PVT with either 1 ml of Wistar-Furth blood, systemic transfusion (SVT), or saline via portal vein (PVSal). After lipopolysaccharide stimulation, 24-hr Kupffer cell supernatant fractions were assayed for PGE2. PGE2 was increased after SVT (1465+/-234 pg/ml) compared with PVSal (597+/-99; P<0.01). PVT increased Kupffer cell PGE2 (5370+/-533; P<0.001 vs. SVT and vs. PVSal) even more substantially. Kupffer cells from PVT-treated rats were then cultured in the presence of inhibitors of PLA2, COX1, or COX2. When Kupffer cells were treated with mepacrine to inhibit PLA2 (5575+/-453 pg/ml), PGE2 production was not different from that by PVSal-treated controls (6467+/-614 pg/ml), but when Kupffer cells were incubated in the presence of the COX1 inhibitor flurbiprofen (3512+/-407 pg/ml) or the COX2 inhibitor nimesulide (2800+/-830 pg/ml), production was decreased 46.7% and 56.7%, respectively, over control activity without added inhibitor. PVT also increased Kupffer cells COX1 and COX2 mRNA as measured by Northern blot. Heart transplants were then performed from Wistar-Furth donors into Lewis recipients at the time of PVT, SVT, PVSal, or PVT + indomethacin (COX1/2 inhibitor). PVT prolonged allograft survival (12.0+/-0.9 days) compared with PVSal (6.3+/-0.3; P<0.01) or SVT (6.3+/-0.3; P<0.04). Indomethacin shortened graft survival when given with PVT (6.5+/-0.3 days). In summary, PVT increased Kupffer cell PGE2 production, up-regulated transcription of Kupffer cells COX1 and COX2 mRNA, and prolonged cardiac allograft survival. COX1/2 inhibition abrogated the effect of PVT. The results indicated that the immunosuppressive effect of PVT may be mediated by up-regulation of Kupffer cell COX1 and COX2. Manipulation of Kupffer cell arachidonic acid metabolism may be useful in augmentation of PVT-induced immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9233713     DOI: 10.1097/00007890-199707150-00023

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  Proposed mechanisms of transfusion-induced immunomodulation.

Authors:  S A Kirkley
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Effect of storage period of red blood cell suspensions on helper T-cell subpopulations.

Authors:  Salih H Bal; Yasemin Heper; Levent T Kumaş; Furkan Guvenc; Ferah Budak; Güher Göral; Haluk B Oral
Journal:  Blood Transfus       Date:  2017-03-15       Impact factor: 3.443

3.  Immune tolerance in liver disease.

Authors:  Ian N Crispe
Journal:  Hepatology       Date:  2014-09-26       Impact factor: 17.425

4.  Mechanism of T cell tolerance induction by murine hepatic Kupffer cells.

Authors:  Qiang You; Linling Cheng; Ross M Kedl; Cynthia Ju
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

Review 5.  Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches.

Authors:  Paola Fisicaro; Valeria Barili; Marzia Rossi; Ilaria Montali; Andrea Vecchi; Greta Acerbi; Diletta Laccabue; Alessandra Zecca; Amalia Penna; Gabriele Missale; Carlo Ferrari; Carolina Boni
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

Review 6.  Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases.

Authors:  Naomi Richardson; Sky T H Ng; David C Wraith
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.